This inventor holds 1 USPTO granted patent. Top assignee: University of Tsukuba. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Yasuyuki Nagumo: Innovator in Medical Chemistry
Introduction
Yasuyuki Nagumo is a prominent inventor based in Tsukuba, Japan. He has made significant contributions to the field of medical chemistry, particularly in the development of compounds that target orexin receptors. His work aims to address various diseases and symptoms related to these receptors, showcasing his commitment to advancing medical science.
Latest Patents
Nagumo holds a patent for a morphinan derivative and its medical usage. The purpose of this invention is to provide a compound that serves as a prophylactic or therapeutic agent for various diseases and symptoms related to orexin receptors. The morphinan derivative, represented by a specific general formula, exhibits excellent selectivity and antagonism against orexin receptors. This compound demonstrates promising therapeutic and prophylactic effects on drug dependence, making it a valuable addition to medical treatments.
Career Highlights
Yasuyuki Nagumo is affiliated with the University of Tsukuba, where he conducts research and develops innovative solutions in medical chemistry. His dedication to his work has led to the creation of impactful inventions that contribute to the understanding and treatment of drug dependence.
Collaborations
Nagumo has collaborated with notable colleagues, including Hiroshi Nagase and Naoshi Yamamoto. These partnerships have fostered a collaborative environment that enhances the research and development of new medical compounds.
Conclusion
Yasuyuki Nagumo's contributions to medical chemistry, particularly through his patent on morphinan derivatives, highlight his role as an innovator in the field. His work not only advances scientific knowledge but also holds the potential to improve therapeutic options for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
